July 17, 2024
VC Firm Oversees NGM Bio’s $122M Series A Funding After Taking it Private
NGM Bio, The Column Group, Venture Capital, Biotech, Series A Funding
Cardurion Pharmaceuticals Raises $260M in Series B Funding to Challenge Statin-Dominated Cardiovascular Market
Cardurion Pharmaceuticals, Series B Funding, Cardiovascular, Statins, Biotech, Bain Capital, Ascenta Capital, NEA, GV, Fidelity Management & Research Company, Millennium Management, Farallon Capital Management, Invus, Blue Owl Healthcare Opportunities, Delos Capital, Digitalis Ventures
Elevance Health Surpasses Expectations in Q2 with $2.3 Billion Profit
Elevance Health, Q2 earnings, profit, revenue, Carelon, PBM, insurance premiums
AstraZeneca Appeals IRA Loss, Reiterates Constitutional Challenge to Drug Price Negotiations
AstraZeneca, IRA, Medicare, Drug Price Negotiation, Constitutional Challenge, Appeal
Roche Continues to Reap Rewards of Carmot Buyout with Strong Early GLP-1 Data
Roche, Carmot Therapeutics, GLP-1/GIP receptor agonist, CT-388, obesity treatment, weight loss, diabetes, pharmaceutical industry
Asceneuron Secures $100 Million in Series C Funding for Dementia Asset Development
Asceneuron, Series C Funding, Dementia Asset, Novo Ventures, Biotech Investment
CordenPharma Invests €900M in Peptide Manufacturing Expansion to Meet Rising Demand for GLP-1 Medications
CordenPharma, GLP-1, peptide manufacturing, expansion, investment, diabetes, obesity, pharmaceutical industry